PMID- 17973263
OWN - NLM
STAT- MEDLINE
DCOM- 20080131
LR  - 20160303
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 122
IP  - 5
DP  - 2008 Mar 1
TI  - HER-2 status discrepancy between primary breast cancer and metastatic sites. 
      Impact on target therapy.
PG  - 999-1004
AB  - In this prospective study, we determined HER-2 status in primary breast invasive 
      carcinomas and in the paired lymph node metastases (synchronous and 
      metachronous), local recurrence and metachronous distant metastases, to verify 
      the percentage of discordant cases. HercepTest and Fluorescence in situ 
      hybridization (FISH) were used to determine HER-2 status on 119 cases of primary 
      infiltrating breast carcinoma and paired metastases (45 cases with synchronous 
      lymph node metastases, 9 cases with metachronous lymph node metastases, 30 cases 
      with local recurrence, and 35 cases with metachronous distant metastases). A 
      therapeutically significant HER-2 status discordance was demonstrated between 
      primary carcinoma and synchronous lymph node metastases (6.7%), local recurrence 
      (13.3%) and metachronous distant metastases (28.6%). In the first comparison, 
      there was a normal HER-2 status in primary tumours and HER-2 amplification in 
      paired metastases, in the second the opposite phenomenon was present, and both 
      types of discordance were evident in the third comparison. Considering the cases 
      of local recurrences and metachronous distant metastases all together, 14 out of 
      65 cases (21.5%) showed a therapeutically significant discordance of HER-2 status 
      between the primary tumour and the paired metachronous recurrence or metastasis 
      (p < 0.001), the 15.4% of cases showing normal HER-2 status in the primary tumour 
      and HER-2 amplification in the neoplastic relapse. For the treatment of 
      metastatic patients, the evaluation of HER-2 status should be performed in 
      neoplastic tissue from metastatic site, whenever possible. This procedure could 
      be also suggested in the patients that are metastatic at the time of diagnosis.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Santinelli, Alfredo
AU  - Santinelli A
AD  - Department of Neuroscience, Polytechnic University of Marche Region, Azienda 
      Ospedaliero-Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi, Via 
      Conca 71, I-60020 Torrette di Ancona, Ancona, Italy. a.santinelli@univpm.it
FAU - Pisa, Eleonora
AU  - Pisa E
FAU - Stramazzotti, Daniela
AU  - Stramazzotti D
FAU - Fabris, Guidalberto
AU  - Fabris G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Int J Cancer. 2008 Sep 15;123(6):1476-7; author reply 1478-9. PMID: 18566999
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*genetics/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis/*genetics/pathology
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics/metabolism/pathology
MH  - Receptor, ErbB-2/*biosynthesis
EDAT- 2007/11/02 09:00
MHDA- 2008/02/01 09:00
CRDT- 2007/11/02 09:00
PHST- 2007/11/02 09:00 [pubmed]
PHST- 2008/02/01 09:00 [medline]
PHST- 2007/11/02 09:00 [entrez]
AID - 10.1002/ijc.23051 [doi]
PST - ppublish
SO  - Int J Cancer. 2008 Mar 1;122(5):999-1004. doi: 10.1002/ijc.23051.